Health
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
WILMINGTON, Del., March 27, 2026--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Tozor
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1438,"height":475,"url":"https://media.zenfs.com/en/business-wire.com/94b0e259512a0b4219e51f781e1aca57"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X7zk.OUiUznDrJr9J2GPKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxNw--/https://media.zenfs.com/en/business-wire.com/94b0e259512a0b4219e51f781e1aca57","width":960,"height":317},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ufVzvBTJiSQusGomA4u.9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03OTI-/https://media.zenfs.com/en/business-wire.com/94b0e259512a0b4219e51f781e1aca57","width":1200,"height":396}},"lazy":false},{"type":"text","content":"First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials","length":185,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., March 27, 2026--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Tozorakimab was generally well tolerated with a favorable safety profile.","length":585,"tagName":"p"},{"type":"text","content":"Tozorakimab is a potential first-in-class monoclonal antibody targeting interleukin-33 (IL-33), that uniquely inhibits the signaling of the reduced and oxidized forms of IL-33, offering the potential to both reduce inflammation and disrupt the cycle of mucus dysfunction that contribute to COPD worsening.1-4 In the OBERON and TITANIA trials, tozorakimab was studied in patients with COPD still experiencing exacerbations while on inhaled standard of care.5,6 Patients received tozorakimab 300mg or placebo on top of standard of care once every four weeks.","length":556,"tagName":"p"},{"type":"text","content":"Nearly 400 million people are diagnosed with COPD, a heterogenous and progressive disease and the 3rd leading cause of death globally.7,8 E...